HB-01

HB-01 is an investigational, once-daily oral fixed-dose combination of **telmisartan** and **verapamil** developed by Honeybrains Biotech for panic disorder and post-traumatic stress disorder. Telmisartan selectively antagonizes the angiotensin II type 1 receptor, while verapamil inhibits calcium influx through L-type calcium channels. HB-01 is intended to modulate physiological stress-response pathways rather than conventional neurotransmitter-centered pathways. A completed Phase 2 panic-disorder study was followed by a larger Phase 2 comparator-controlled panic-disorder study, and a Phase 2 PTSD study has also been registered. ([cdek.pharmacy.purdue.edu](https://cdek.pharmacy.purdue.edu/trial/NCT06483789/))

Other names

telmisartan + verapamil